Published in Gut on September 06, 2006
Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut (2011) 2.87
Is obesity a risk factor for Crohn's disease? Dig Dis Sci (2011) 1.64
Adipocytes as a Link Between Gut Microbiota-Derived Flagellin and Hepatocyte Fat Accumulation. PLoS One (2016) 1.40
Where are all the Mycobacterium avium subspecies paratuberculosis in patients with Crohn's disease? PLoS Pathog (2009) 1.02
Dietary n-3 polyunsaturated fatty acids (PUFA) decrease obesity-associated Th17 cell-mediated inflammation during colitis. PLoS One (2012) 0.99
Adipose tissue and inflammatory bowel disease pathogenesis. Inflamm Bowel Dis (2012) 0.98
Endocrine and metabolic manifestations in inflammatory bowel disease. Ann Gastroenterol (2012) 0.93
Substance P promotes expansion of human mesenteric preadipocytes through proliferative and antiapoptotic pathways. Am J Physiol Gastrointest Liver Physiol (2009) 0.91
Adipose-tissue and intestinal inflammation - visceral obesity and creeping fat. Front Immunol (2014) 0.88
Association of clinical and radiographic features with perinephric "sticky" fat. J Endourol (2012) 0.87
Extraluminal factors contributing to inflammatory bowel disease. World J Gastroenterol (2011) 0.87
Decreased levels of serum omentin-1 in patients with inflammatory bowel disease. Med Sci Monit (2015) 0.86
Serum levels and mesenteric fat tissue expression of adiponectin and leptin in patients with Crohn's disease. Clin Exp Immunol (2012) 0.86
The role of physical exercise in inflammatory bowel disease. Biomed Res Int (2014) 0.84
Metabolic syndrome frequency in inflammatory bowel diseases. Saudi J Gastroenterol (2011) 0.84
Prevalence of metabolic syndrome is comparable between inflammatory bowel disease patients and the general population. J Gastroenterol (2010) 0.83
The effect of body weight on the severity and clinical course of ulcerative colitis. Int J Colorectal Dis (2014) 0.82
Toll-like receptor 4, F4/80 and pro-inflammatory cytokines in intestinal and mesenteric fat tissue of Crohn's disease. Int J Clin Exp Med (2013) 0.82
Reciprocal Inflammatory Signaling Between Intestinal Epithelial Cells and Adipocytes in the Absence of Immune Cells. EBioMedicine (2017) 0.82
Frequency and significance of the novel single nucleotide missense polymorphism Val109Asp in the human gene encoding omentin in Caucasian patients with type 2 diabetes mellitus or chronic inflammatory bowel diseases. Cardiovasc Diabetol (2007) 0.81
High-sensitivity C-reactive protein in paediatric inflammatory bowel disease. World J Gastroenterol (2010) 0.80
Moderate exercise training attenuates the severity of experimental rodent colitis: the importance of crosstalk between adipose tissue and skeletal muscles. Mediators Inflamm (2015) 0.80
Inflammatory cytokine gene expression in mesenteric adipose tissue during acute experimental colitis. PLoS One (2013) 0.78
Defective apoptosis in intestinal and mesenteric adipose tissue of Crohn's disease patients. PLoS One (2014) 0.77
Transcriptional and Molecular Pathways Activated in Mesenteric Adipose Tissue and Intestinal Mucosa of Crohn's Disease Patients. Int J Inflam (2017) 0.76
Inflammation: an equal-opportunity process. Dig Dis Sci (2011) 0.75
Disease Phenotype, Activity and Clinical Course Prediction Based on C-Reactive Protein Levels at Diagnosis in Patients with Crohn's Disease: Results from the CONNECT Study. Gut Liver (2016) 0.75
Fibroblast Growth Factor 21 Deficiency Attenuates Experimental Colitis-Induced Adipose Tissue Lipolysis. Gastroenterol Res Pract (2017) 0.75
Adipocyte-Epithelial Interactions and Crohn's Disease - An Emerging Drug Target. EBioMedicine (2017) 0.75
Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis. Pharm Res (2017) 0.75
The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A (2004) 26.56
The hormone resistin links obesity to diabetes. Nature (2001) 15.49
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS (1998) 8.88
Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr (2004) 6.31
Evidence for a role of developmental genes in the origin of obesity and body fat distribution. Proc Natl Acad Sci U S A (2006) 4.81
Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med (2006) 4.35
Preadipocyte conversion to macrophage. Evidence of plasticity. J Biol Chem (2003) 3.91
Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest (1998) 3.76
Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation (2003) 3.73
Resistin, an adipokine with potent proinflammatory properties. J Immunol (2005) 3.63
The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest (1995) 3.39
Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun (2003) 3.16
Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J Clin Invest (1996) 2.98
Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract (2004) 2.95
Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest (1997) 2.73
Leptin in immunology. J Immunol (2005) 2.62
Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun (2004) 2.32
Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res (2005) 2.28
Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. Gastroenterol Clin Biol (2003) 2.26
Crystal structure of the obese protein leptin-E100. Nature (1997) 2.22
Increased adiposity in animals due to a human virus. Int J Obes Relat Metab Disord (2000) 2.22
Adipocyte-derived hormones, cytokines, and mediators. Endocrine (2006) 2.04
Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease. Gut (2005) 2.03
Leptin: a pivotal mediator of intestinal inflammation in mice. Gastroenterology (2002) 1.96
Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease. Gut (2001) 1.92
Adipocytokines: leptin--the classical, resistin--the controversical, adiponectin--the promising, and more to come. Best Pract Res Clin Endocrinol Metab (2005) 1.87
The lipopolysaccharide-activated toll-like receptor (TLR)-4 induces synthesis of the closely related receptor TLR-2 in adipocytes. J Biol Chem (2000) 1.87
Adipose tissue: a regulator of inflammation. Best Pract Res Clin Endocrinol Metab (2005) 1.86
Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology (1999) 1.68
Adiponectin inhibits LPS-induced NF-kappaB activation and IL-6 production and increases PPARgamma2 expression in adipocytes. Am J Physiol Regul Integr Comp Physiol (2004) 1.62
Insulin resistance and body fat distribution. Diabetes Care (1996) 1.57
Role of resistin in inflammation and inflammation-related diseases. Cell Mol Immunol (2006) 1.53
Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet (2002) 1.50
A preliminary study of growth hormone therapy for Crohn's disease. N Engl J Med (2000) 1.41
Inflamed about obesity. Nat Med (2004) 1.37
Fat-wrapping in Crohn's disease: pathological basis and relevance to surgical practice. Br J Surg (1992) 1.36
Truncal adiposity, relative growth hormone deficiency, and cardiovascular risk. J Clin Endocrinol Metab (2004) 1.31
Review article: adipocytokines and insulin resistance. Aliment Pharmacol Ther (2005) 1.30
Adiponectin induces TNF-alpha and IL-6 in macrophages and promotes tolerance to itself and other pro-inflammatory stimuli. Biochem Biophys Res Commun (2005) 1.26
Leptin receptor expression on T lymphocytes modulates chronic intestinal inflammation in mice. Gut (2004) 1.17
Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. Am J Clin Nutr (1999) 1.16
Intraoperative enteroscopy in Crohn's disease. Br J Surg (1993) 1.14
Adiponectin and its gene variants as risk factors for insulin resistance, the metabolic syndrome and cardiovascular disease. Atherosclerosis (2006) 1.13
A human adenovirus enhances preadipocyte differentiation. Obes Res (2004) 1.12
Adiponectin, an adipocyte-derived protein. Physiol Res (2005) 1.10
Adiponectin stimulates proliferation and cytokine secretion in colonic epithelial cells. Regul Pept (2006) 1.10
Disorders of fat distribution in HIV infection. Int J STD AIDS (1998) 1.09
Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines. J Biol Chem (2004) 1.07
Nocturnal growth hormone and gonadotrophin secretion in growth retarded children with Crohn's disease. Gut (1981) 1.05
Regulation of tumour necrosis factor-alpha release from human adipose tissue in vitro. J Endocrinol (1999) 1.04
Human adipose cells express CD4, CXCR4, and CCR5 [corrected] receptors: a new target cell type for the immunodeficiency virus-1? FASEB J (2002) 1.01
Expression of macrophage-colony stimulating factor in normal and inflammatory bowel disease intestine. J Pathol (2001) 1.01
Inhibition by adiponectin of IL-8 production by human macrophages upon coculturing with late apoptotic cells. Biochem Biophys Res Commun (2005) 0.99
The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol (2005) 0.98
Leptin mediates Clostridium difficile toxin A-induced enteritis in mice. Gastroenterology (2003) 0.95
Long-term changes in adipose tissue in human disease. Proc Nutr Soc (2001) 0.95
Role of leptin in immunology. Nutr Rev (2002) 0.94
Insulin like growth factor-I, insulin like growth factor binding protein-1, and insulin in childhood Crohn's disease. Gut (1993) 0.90
Recognition of regional ileitis in the operating room. Dis Colon Rectum (1971) 0.89
Adipose tissue, the anatomists' Cinderella, goes to the ball at last, and meets some influential partners. Postgrad Med J (2000) 0.84
Defining obesity in childhood: current practice. Am J Clin Nutr (1999) 0.83
Effects of growth hormone secretion on body composition in patients with Crohn's disease. J Clin Endocrinol Metab (2003) 0.82
Levels of the adipocyte-derived plasma protein, adiponectin, have a close relationship with atheroma. Thromb Res (2005) 0.80
Effect of Chlamydia pneumoniae infection and hyperlipidaemia on the expression of PPARgamma, P50 and c-Fos in aortic endothelial cells in C57bL/6J mice. Acta Cardiol (2005) 0.79
Measurement of body fat and fat distribution. J Nurs Meas (1995) 0.78
Variability of abdominal adipose tissue measurements using computed tomography in prepubertal girls. Int J Obes Relat Metab Disord (1998) 0.77
Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science (2005) 11.31
Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem (2003) 10.79
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology (2004) 5.94
CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet (2002) 5.31
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med (2007) 4.39
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc (2004) 4.12
Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med (2013) 3.98
Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology (2011) 3.81
Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology (2013) 3.45
Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. Nat Genet (2010) 3.22
Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology (2011) 3.08
Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology (2003) 3.05
NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J Clin Invest (2013) 2.96
Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology (2012) 2.95
Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut (2011) 2.87
Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition. EMBO J (2004) 2.81
A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology (2005) 2.70
Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology (2003) 2.59
The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology (2002) 2.58
CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J Clin Invest (2007) 2.44
Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol (2008) 2.44
Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology (2008) 2.39
Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol (2009) 2.36
Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol (2009) 2.27
Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. Gastroenterol Clin Biol (2003) 2.26
Molecular inventory of faecal microflora in patients with Crohn's disease. FEMS Microbiol Ecol (2004) 2.21
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med (2006) 2.16
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol (2008) 2.15
Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury. Proc Natl Acad Sci U S A (2011) 2.12
Crohn disease--associated adherent-invasive E. coli bacteria target mouse and human Peyer's patches via long polar fimbriae. J Clin Invest (2011) 2.10
Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med (2005) 2.06
Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology (2012) 2.03
Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut (2012) 1.97
Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. Am J Gastroenterol (2002) 1.94
Geographical variability and environmental risk factors in inflammatory bowel disease. Gut (2013) 1.84
Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol (2010) 1.82
The capacity of nondigestible carbohydrates to stimulate fecal bifidobacteria in healthy humans: a double-blind, randomized, placebo-controlled, parallel-group, dose-response relation study. Am J Clin Nutr (2004) 1.82
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut (2011) 1.80
Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. Inflamm Bowel Dis (2010) 1.78
Fibrin glue is effective healing perianal fistulas in patients with Crohn's disease. Gastroenterology (2010) 1.73
A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm Bowel Dis (2006) 1.70
Complete genome sequence of Crohn's disease-associated adherent-invasive E. coli strain LF82. PLoS One (2010) 1.69
Specific recognition of Candida albicans by macrophages requires galectin-3 to discriminate Saccharomyces cerevisiae and needs association with TLR2 for signaling. J Immunol (2006) 1.63
Binding of Escherichia coli adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA. Proc Natl Acad Sci U S A (2002) 1.63
Stress-induced disruption of colonic epithelial barrier: role of interferon-gamma and myosin light chain kinase in mice. Gastroenterology (2003) 1.53
Impact of Small Bowel Exploration Using Video-Capsule Endoscopy in the Management of Acute Gastrointestinal Graft-versus-Host Disease. Transplantation (2004) 1.51
Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet (2002) 1.50
Small bowel capsule endoscopy for management of Crohn's disease: a retrospective tertiary care centre experience. Dig Liver Dis (2012) 1.49
CD8+ cytotoxic T cells induce relapsing colitis in normal mice. Gastroenterology (2006) 1.47
Pancreatic changes in TNBS-induced colitis in mice. Gastroenterol Clin Biol (2003) 1.47
Incidence, clinical presentation and location at diagnosis of pediatric inflammatory bowel disease: a prospective population-based study in northern France (1988-1999). J Pediatr Gastroenterol Nutr (2005) 1.45
[Molecular consequences of fixation and tissue processing: the examples of nucleic acids and proteins]. Ann Pathol (2006) 1.43
Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation. J Clin Invest (2003) 1.40
Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterology (2004) 1.38
LRH-1-mediated glucocorticoid synthesis in enterocytes protects against inflammatory bowel disease. Proc Natl Acad Sci U S A (2007) 1.35
Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology (2005) 1.33
Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci U S A (2010) 1.29
The natural history of pediatric ulcerative colitis: a population-based cohort study. Am J Gastroenterol (2009) 1.29
Indeterminate colitis: a review of the concept--what's in a name? Inflamm Bowel Dis (2008) 1.28
Colonization of mice by Candida albicans is promoted by chemically induced colitis and augments inflammatory responses through galectin-3. J Infect Dis (2008) 1.25
Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease. PLoS One (2009) 1.24
Mapping of inflammatory bowel disease in northern France: spatial variations and relation to affluence. Inflamm Bowel Dis (2010) 1.23
Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut (2013) 1.22
A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol (2012) 1.22
Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol (2008) 1.21
Optimising monitoring in the management of Crohn's disease: a physician's perspective. J Crohns Colitis (2013) 1.20
Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol (2010) 1.19
Intestinally secreted C-type lectin Reg3b attenuates salmonellosis but not listeriosis in mice. Infect Immun (2012) 1.19
Aseptic abscesses: a study of 30 patients with or without inflammatory bowel disease and review of the literature. Medicine (Baltimore) (2007) 1.17
Adherent-invasive Escherichia coli isolated from Crohn's disease patients induce granulomas in vitro. Cell Microbiol (2007) 1.16
A novel caspase-1/toll-like receptor 4-independent pathway of cell death induced by cytosolic Shigella in infected macrophages. J Biol Chem (2005) 1.16
Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol (2010) 1.15
GW501516-activated PPARβ/δ promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation. Cell Biosci (2012) 1.15
Use of mouse models to evaluate the persistence, safety, and immune modulation capacities of lactic acid bacteria. Clin Diagn Lab Immunol (2003) 1.14
Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology (2013) 1.14
Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn's disease. Gastroenterology (2006) 1.12